Please login to the form below
CAR-T therapies
This page shows the latest CAR-T therapies news and features for those working in and with pharma, biotech and healthcare.
ASCO: Momentum gathers behind next wave of CAR-T therapies
This year’s virtual ASCO congress included dozens of presentations on CAR-T therapies, including an update from one of the two currently approved therapies – Gilead Sciences’ Yescarta – and new data ... If approved, the off-the-shelf CAR-T would
Latest news
-
Roche/Gilead tag team fights COVID-19 with Actemra/remdesivir
patients. The drug has been shown to cut the recovery time for people hospitalised with severe coronavirus symptoms, although it doesn’t seem to be as effective in those who are ... CAR-T cell therapies for cancer.
-
EMA clears BMS’ oral multiple sclerosis drug Zeposia
It’s one of three products – along with two CAR-T therapies – that need to reach the market by March of next year to generate a $9 contingent value right (CVR) ... While Zeposia has hit the deadline comfortably, the CVR payout has been jeopardised
-
EMA starts review of MorphoSys’ tafasitamab for lymphoma
Drug could challenge Novartis and Gilead’s CAR-T therapies if approved. The EMA has started its review of MorphoSys’ anti-CD19 antibody tafasitamab (MOR208), setting up a possible challenge to ... Novartis and Gilead’s CAR-T therapies if approved
-
FDA approves Roche’s Actemra COVID-19 trial
It was first cleared by the FDA as a treatment for rheumatoid arthritis and has also subsequently been approved in juvenile idiopathic arthritis, giant cell arteritis and CRS associated with ... T cell therapies for cancer.
-
China backs use of Roche’s Actemra for coronavirus
and CRS associated with CAR-T cell therapies for cancer.
More from news
Approximately 5 fully matching, plus 86 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
Thanks to the CAR construct, the engineered T cells can recognise and attack the CD19-expressing cancer cells. ... This composition could confer efficacy and safety advantages, including fewer adverse effects such as cytokine release syndrome (CRS) and
-
China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances
At the spear point is China’s emergence as the epicentre of biotech research and development, with its performance on CAR-T therapies turning heads. ... We are introducing the international best practices of developing CAR T to our China team and
-
European biotech: a new generation of leaders emerges
year. The promise of the molecule is great, with analysts seeing it as a possible challenge to Novartis and Gilead’s CAR-T therapies. ... This means its clinical outcomes could match those seen in the CAR-Ts, but without the complexity and cost of
-
The dawn of a new era in medical education
Innovation is not without its challenges. Let’s take haematology as our case study; there has been a flurry of revolutionary cell therapies to treat blood cancers, including CAR-T therapies. ... therapies, where the administration is not as simple as
-
25 Women Leaders in UK Healthcare (part 2)
It has brought to market not one but two groundbreaking drugs in hepatitis C, Harvoni, and in diffuse large B cell lymphoma, Yescarta, one of the first CAR-T therapies to ... This is demonstrated in Gilead securing two truly groundbreaking partnerships
More from intelligence
Approximately 0 fully matching, plus 24 partially matching documents found.
Latest appointments
-
Health comms agency emotive hires new cell and gene therapy leader
It is also charged with developing HCP engagement on gene silencing technology and educating on cell therapies such as CAR-T, and the new business unit will provide core expertise in ... He says this will be needed to ensure advanced therapies realise
-
Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult and more
Ceylad appoints new CFO. Clinical-stage biopharma focused on the development of CAR-T cell therapies has announced that Filippo Petti has been appointed as Chief Financial Officer. ... He said: “Celyad’s differentiated approach to the field of CAR-T
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Precision paediatrics: Treating patients with CAR-T
It’s an exciting time for CAR-T therapy. SA: It’s an integrated, holistic approach. ... This approach can make targeted therapies like CAR-T a reality. A good example at GOSH is in bone marrow transplants.
-
Highlights in haematologic malignancy from ASH 2018
However, CAR T-cell therapies stop working in some patients and severe toxicity can also occur. ... Other abstracts reported on CAR T-cell therapies for multiple myeloma directed against the B-cell maturation antigen (BCMA).
-
Download our infographic: Addressing the biggest challenges for rare disease communities
Recently these have included advanced genetic therapies, such as viral mediated gene transfer and CAR-T therapies.
-
Training the next generation of biotech leaders
In this year alone, the FDA has taken the groundbreaking step of approving two CAR-T therapies. ... The approval of two CAR-T therapies this year illustrates how cell and gene therapies are turning from scientific dream to reality, with companies in the
-
Addressing the biggest challenges for rare disease communities
It is common that primary care physicians either do not recognise specific symptoms or don’t make the link between common symptoms and a rare disease. ... year, we saw landmark breakthroughs in advanced genetic therapies, such as viral mediated gene
More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Biogen delays filing of Alzheimer’s drug, which hits its share price
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Alnylam and Vir plan gene-silencing attack on COVID-19 virus
- Merck’s Keytruda hits the mark in triple negative breast cancer
- Finalists 2020 - Communiqué Awards
- ASCO: Momentum gathers behind next wave of CAR-T therapies
- Lilly starts world first trial of an antibody drug for COVID-19
- Pfizer’s Ibrance misses the mark in early breast cancer
- Rise of the patient influencer
- Working together against COVID-19
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
PMHub
Wisepress
Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...
Latest intelligence
- Working together against COVID-19
- Analysing social media conversations to see what HCPs are saying online about the global pandemic...
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
- Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
- Are biobetters a market access opportunity?
- Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....
Quick links
Infographics
